Reardon Tighe
Known title: Acting Chief Financial OfficerCIK: 0001760431
Reardon Tighe's purchase track record
Reardon Tighe has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/13/2023 | JANX | $4.99M | +21.4% | +605.1% | +18.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| JANX | ▼ Sell | Open Market | 131,196 | $7.2M | 6/3/2024 | View on chart |
| JANX | ▼ Sell | Open Market | 691,525 | $37.9M | 6/3/2024 | View on chart |
| JANX | ▲ Buy | Open Market | 849,854 | $5.0M | 11/13/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Janux Therapeutics draws fresh attention amid valuation concerns
Recent articles have put Janux Therapeutics back in focus after a 110% price increase over the past period. Analysts note that the stock may appear overvalued given its rapid run, with target prices ranging from $14 to $75 and an average of $36.24. The discussion comes as the shares trade near the upper end of their 52‑week range. Market participants are watching the valuation debate closely.
Janux Therapeutics draws fresh attention amid valuation concerns. Recent articles have put Janux Therapeutics back in focus after a 110% price increase over the past period. Analysts note that the stock may appear overvalued given its rapid run, with target prices ranging from $14 to $75 and an average of $36.24. The discussion comes as the shares trade near the upper end of their 52‑week range. Market participants are watching the valuation debate closely.